Vertex says FDA reviews CASGEVY label expansion to younger children with sickle cell, beta thalassemia

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

0.00
  • Vertex filed to expand CASGEVY to younger children, with FDA review underway in the US.
  • Regulatory submissions also completed in Saudi Arabia and the UK to extend use below age 12.
  • CASGEVY is currently cleared in several markets for eligible patients aged 12 and older with SCD or transfusion-dependent beta thalassemia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260610130971) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.